Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Toksični megakolon posle iracionalne primene antibiotika u lečenju trudnice sa Covid-om 19: prikaz slučaja. ; 9(2):1189-1195, 2022.
Article in English | Academic Search Complete | ID: covidwho-2025241

ABSTRACT

Introduction: Optimal management of toxic megacolon as a consequence of Cl. difficile colitis is still matter of controversy, as well as timing of available therapeutic modalities. In this article we report a case of severe C. difficile colitis associated with toxic megacolon in a pregnant patient with Covid 19, who was successfully treated conservatively. Case Report: A 33-years old pregnant woman contracted SARS-CoV-2 in the 32nd week of pregnancy. She was admitted to regional hospital and treated extensively by wide-spectrum antibiotics. After the delivery she developed severe form of Cl. difficile colitis with toxic megacolon. In spite of severe clinical picture, the patient was treated conservatively, with high initial oral doses of vancomycin, with subsequent tapering. The outcome of the treatment was complete recovery and colonic functions were regained completely. Conclusion: In conclusion, our case shows that in younger patients, who were fit before occurrence of Cl. difficile colitis and toxic megacolon, conservative therapy should be tried as long as possible before turning to colectomy, since chances for cure without surgery are considerable. (English) [ FROM AUTHOR] Uvod: Optimalno upravljanje toksičnim megakolonom kao posledicom Cl. difficile kolitis je još uvek predmet kontroverzi, kao i vreme kada su dostupni terapijski modaliteti. U ovom članku izveštavamo o slučaju teškog kolitisa C. difficile povezanog sa toksičnim megakolonom kod trudnice sa Covid-om 19, koja je uspešno lečena konzervativno. Prikaz slučaja: Trudnica stara 33 godine zarazila se SARS-CoV-2 u 32. nedelji trudnoće. Primljena je u regionalnu bolnicu i intenzivno lečena antibioticima širokog spektra. Nakon porođaja razvila je teški oblik Cl. difficile kolitis sa toksičnim megakolonom. I pored teške kliničke slike, pacijent je lečen konzervativno, visokim početnim oralnim dozama vankomicina, uz naknadno smanjivanje. Ishod lečenja je bio potpuni oporavak i potpuno su vraćene funkcije debelog creva. Zaključak: U zaključku, naš slučaj pokazuje da kod mlađih pacijenata, koji su bili u formi pre pojave Cl. difficile kolitisa i toksičnog megakolona, konzervativnu terapiju treba pokušavati što je duže moguće pre nego što se pređe na kolektomiju, pošto su šanse za izlečenje bez operacije znatne. (Bosnian) [ FROM AUTHOR] Copyright of Hospital Pharmacology: International Multidisciplinary Journal is the property of Serbian Medical Society, Section for Clinical Pharmacology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

2.
Front Public Health ; 10: 972668, 2022.
Article in English | MEDLINE | ID: covidwho-2022998

ABSTRACT

Validation of the fear of introduction: High levels of fear of COVID-19 may be associated with increased levels of stress, anxiety, and depression, as well as decreased resilience and life expectancy. Objective: This study aimed to translate and confirm the Serbian version of the Fear of COVID-19 scale as well as to investigate its psychometric properties. Methods: The translation and intercultural adaptation of the Fear of COVID-19 scale was performed by the leading standard of the International Society for Pharmacoeconomics and Outcome Research. When the distribution was normal, the Kolmogorov-Smirnov test was used. The reliability of the Serbian version of FCV-19S was tested by measuring the internal consistency through the value of Cronbach's alpha. Results: The original version of the Fear of COVID-19 scale was tested on a sample of 256 subjects with a mean age of 25.38 ± 12.47. The Cronbach's alpha value was 0.864. We divided the scale by the split-half method (Spearman-Brown), and the value of the coefficient for the questionnaire as a whole was 0.882. Divergent criterion validity was tested through the non-parametric correlation between the scores of the Fear of COVID-19 scale and the Fear of Hospitalization scale. A score of the Fear of COVID-19 scale was calculated as the sum of each question for each of the respondents. Convergent criterion validity was tested through the non-parametric correlation between the scores of the Fear of COVID-19 scale and the Emotional Regulation Questionnaire. Conclusion: The validated version of the scale in Serbia complements versions available in other cultures and other languages and facilitates global studies related to mental health during the COVID-19 pandemic.


Subject(s)
COVID-19 , Adolescent , Adult , Balkan Peninsula , COVID-19/diagnosis , COVID-19/epidemiology , Child , Fear/psychology , Humans , Pandemics , Reproducibility of Results , Serbia/epidemiology , Young Adult
3.
Serbian Journal of Experimental & Clinical Research ; : 1, 2022.
Article in English | Academic Search Complete | ID: covidwho-1785291

ABSTRACT

This aim of this study was to identify potential factors associated with survival in patients with coronavirus disease 2019 (COVID- 19). This study was designed as a case series. It included patients hospitalized in Clinical Centre Kragujevac between March 10, 2020, and June 15, 2020, due to COVID-19. Variables with significant influence on the cure of patients were identified by multivariate logistic regression. A total of 234 patients were included. The average age of the patients was 57.2 ± 15.8 years. Thirty-five patients died (15.0%) and 199 (85.0%) were discharged as completely cured and with the sustained virological response.The study variables with significant influence (expressed as odds ratio – OR) on cure of COVID-19 patients after adjustment for effects of other variables were: stay in an intensive care unit – ICU (OR = 0.007;95% confidence interval – CI 0.001 – 0.086;p = 0.000), previous hospitalization (OR = 7.802;95% CI 1.198 – 50.924;p = 0.032), increased body temperature on admission (OR = 0.004;95% CI 0.000 – 0.771;p = 0.040), higher score of the Charlson Comorbidity Index (OR = 0.428;95% CI 0.235 – 0.780;p = 0.006), and increased values of C-reactive protein (CRP) serum level (OR = 0.978;95% CI 0.966 – 0.990;p = 0.000). In conclusion, clinicians should pay attention to patients with high body temperature at admission, presence of multiple comorbidities, high CRP, and patients who stay in an ICU, considering that they could be at risk for fatal outcome. [ FROM AUTHOR] Copyright of Serbian Journal of Experimental & Clinical Research is the property of Sciendo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

4.
J Med Virol ; 94(6): 2402-2413, 2022 06.
Article in English | MEDLINE | ID: covidwho-1718416

ABSTRACT

The aim of this study is to provide a more accurate representation of COVID-19's case fatality rate (CFR) by performing meta-analyses by continents and income, and by comparing the result with pooled estimates. We used multiple worldwide data sources on COVID-19 for every country reporting COVID-19 cases. On the basis of data, we performed random and fixed meta-analyses for CFR of COVID-19 by continents and income according to each individual calendar date. CFR was estimated based on the different geographical regions and levels of income using three models: pooled estimates, fixed- and random-model. In Asia, all three types of CFR initially remained approximately between 2.0% and 3.0%. In the case of pooled estimates and the fixed model results, CFR increased to 4.0%, by then gradually decreasing, while in the case of random-model, CFR remained under 2.0%. Similarly, in Europe, initially, the two types of CFR peaked at 9.0% and 10.0%, respectively. The random-model results showed an increase near 5.0%. In high-income countries, pooled estimates and fixed-model showed gradually increasing trends with a final pooled estimates and random-model reached about 8.0% and 4.0%, respectively. In middle-income, the pooled estimates and fixed-model have gradually increased reaching up to 4.5%. in low-income countries, CFRs remained similar between 1.5% and 3.0%. Our study emphasizes that COVID-19 CFR is not a fixed or static value. Rather, it is a dynamic estimate that changes with time, population, socioeconomic factors, and the mitigatory efforts of individual countries.


Subject(s)
COVID-19 , Asia , COVID-19/epidemiology , Europe/epidemiology , Humans , SARS-CoV-2 , Socioeconomic Factors
5.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-293427

ABSTRACT

Introduction: Aim of our study was to identify total costs of COVID-19 inpatients treatment in an upper-middle income country from Southeast Europe. Methods: This retrospective, observational cost of illness study was performed from National Health Insurance Fund perspective and included a cohort of 118 males and 78 females admitted to COVID-19 ward units of a tertiary center, during the first wave of epidemics. Results: The median of total costs in the non-survivors′ subgroup (n=43) was 3279.16 Euro (4023.34, 355.20, 9909.61) which is higher than in the survivors (n=153) subgroup 747.10 Euro (1088.21, 46.71, 3265.91). The odds ratio of Charlson Comorbidity Index total score and every 100-Euros increase of patient′s total hospital treatment costs for fatal outcome were 1.804 (95% confidence interval 1.408-2.311, p<0.001) and 1.050 (1.029-1.072, p<0.001), respectively. Conclusions: Direct medical treatment costs for COVID-19 inpatients represent significant economic burden. The link between increased costs and unfavorable final outcome should be further explored.

SELECTION OF CITATIONS
SEARCH DETAIL